Is Verastem, Inc. (NASDAQ:VSTM) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Verastem, Inc. at current levels.
First approved therapy for recurrent low-grade serous ovarian cancer with a confirmatory readout that either doubles the stock or halves it.
Where VSTM is headed
Verastem's story pivots on one number that arrives in 2027: the RAMP 301 confirmatory readout for the avutometinib/defactinib combo in recurrent low-grade serous ovarian cancer (LGSOC). The accelerated approval of AVMAPKI FAKZYNJA CO-PACK in May 2024 already gave Verastem the first and only FDA-approved therapy for this orphan indication, a patient population that has spent decades cycling through chemo regimens that barely move the needle. Commercial launch is in the awkward early-innings phase where revenue is real but small, gross-to-net is ugly, and the sales force is still educating gynecologic oncologists who see maybe two or three of these patients a year.
Read the full Compass Direction on VSTM
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $8.11).
See the full VSTM analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Verastem, Inc. (NASDAQ:VSTM) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Verastem, Inc. at current levels. First approved therapy for recurrent low-grade serous ovarian cancer with a confirmatory readout that either doubles the stock or halves it.
What is VSTM's Compass Score?
Verastem, Inc. scores 82/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for VSTM?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the VSTM page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.